A Survey of Genome Editing Activity for 16 Cpf1 orthologs

Bernd Zetsche, Jonathan Strecker, Omar O. Abudayyeh, Jonathan S. Gootenberg, David Scott, Feng ZhangbioRxiv 2017 · DOI

TL;DR

This paper expands the genome editing toolbox by identifying and characterizing 16 new Cpf1 orthologs for use in eukaryotic cells. Notably, they found that Moraxella bovoculi AAX11_00205 (Mb3Cpf1) exhibits robust activity and a more relaxed PAM recognition than previously known Cpf1 enzymes, opening up new possibilities for targeted gene editing.

What Problem Does This Paper Address?

CRISPR-Cas systems have revolutionized genome engineering, with Cas9 being the most widely used. However, the Cpf1 endonuclease, a class 2 CRISPR system, offers distinct advantages such as processing its own guide RNA array and requiring only a single RNA guide. These features make Cpf1 particularly attractive for applications like multiplexed gene editing and targeting AT-rich regions. Despite its promise, the repertoire of active Cpf1 orthologs in eukaryotic systems was limited. This paper addresses the need to expand this repertoire by systematically screening and evaluating a larger set of Cpf1 orthologs for their nuclease activity in human cells, aiming to discover new enzymes with potentially improved or distinct properties.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatic Selection: They computationally searched for Cpf1 orthologs, selecting 16 candidates based on homology to previously characterized active Cpf1 enzymes.
  • In Vitro PAM Identification: An in vitro assay was used to determine the Protospacer Adjacent Motif (PAM) sequences recognized by each Cpf1 ortholog. This involved incubating Cpf1 nucleases with a library of DNA targets containing randomized PAM sequences and identifying which PAMs were cleaved.
  • Eukaryotic Cell Activity Assays:
    • HEK293T Cell Transfection: Human codon-optimized Cpf1 orthologs and their corresponding guide RNAs (crRNAs) were expressed in HEK293T cells.
  • Indel Detection: The Surveyor nuclease assay was used to detect insertion/deletion (indel) events at targeted genomic loci, indicating nuclease activity.
  • Deep Sequencing: For more detailed analysis, deep sequencing was employed to quantify indel frequencies at target sites.
  • PAM Specificity Testing: For promising candidates, further experiments were conducted to assess their activity with different PAM sequences, including relaxed or non-canonical ones.

Datasets

Not discussed in the paper. The study primarily relies on in vitro assays and experiments conducted in cultured human cells (HEK293T).

Key Insights and Ideas

  • Expanding the Cpf1 Toolbox: The study successfully identified four new Cpf1 orthologs that exhibit activity in human cells, significantly broadening the available options for Cpf1-mediated genome editing.
  • Mb3Cpf1: A Promising New Enzyme: Moraxella bovoculi AAX11_00205 (Mb3Cpf1) emerged as a standout, demonstrating robust indel formation comparable to established Cpf1 enzymes like AsCpf1 and LbCpf1.
  • Relaxed PAM Recognition: A key finding is that Mb3Cpf1 shows tolerance for a shortened PAM sequence (TTN) in addition to the canonical TTTV PAM. This flexibility in PAM recognition is highly valuable, as it can increase the number of potential target sites within a genome.
  • Ortholog-Specific Activity: The research highlights that different Cpf1 orthologs can have varying PAM specificities and activity levels, underscoring the importance of screening diverse orthologs for specific applications.
  • Conserved crRNA Maturation: The high homology observed in the stem structure and AAUU motif of Cpf1 direct repeats suggests a conserved mechanism for crRNA maturation across the Cpf1 family.

Key Results

  • Four active orthologs identified: Thiomicrospira sp. Xs5 (TsCpf1), Moraxella bovoculi AAX08_00205 (Mb2Cpf1), Moraxella bovoculi AAX11_00205 (Mb3Cpf1), and Butyrivibrio sp. NC3005 (BsCpf1) showed detectable indel events in human cells.
  • Mb3Cpf1's robust activity: Mb3Cpf1 achieved indel frequencies of >20% with multiple guides and showed activity comparable to AsCpf1 and LbCpf1.
  • Mb3Cpf1's relaxed PAM: Mb3Cpf1 demonstrated activity at TTN PAMs, albeit with lower efficiency than at TTTV PAMs. It also showed activity at RTTV PAMs.
  • Comparison of activity: At TTTV PAMs, Mb3Cpf1 showed an average activity of ~18%, while AsCpf1 was ~28% and LbCpf1 was ~13%. At NTTN PAMs, Mb3Cpf1 had an average activity of ~5.3%, compared to ~2.7% for AsCpf1 and ~1.4% for LbCpf1.

Limitations and Future Work

  • Organism-Specific Activity: The authors note that Cpf1 ortholog activity can be organism-dependent, citing a previous study showing weak FnCpf1 activity in mammalian cells but robust activity in plant cells. This suggests that further validation in various organisms may be necessary.
  • Further PAM Exploration: While Mb3Cpf1's relaxed PAM recognition was explored, there's potential for deeper investigation into its full PAM tolerance and the precise rules governing its recognition.
  • Optimization for Specific Applications: The newly identified orthologs, particularly Mb3Cpf1, could be further engineered or optimized for specific genome editing applications, potentially enhancing their efficiency or specificity.
  • Multiplexing Potential: The paper mentions Cpf1's utility in multiplexed gene targeting. Future work could explore the multiplexing capabilities of these newly characterized orthologs.

Summary updated

Abstract

Summary The recently discovered class 2 CRISPR-Cas endonuclease Cpf1 offers several advantages over Cas9, including the ability to process its own array and requirement for just a single RNA guide. These attributes make Cpf1 promising for many genome engineering applications. To further expand the suite of Cpf1 tools available, we tested 16 Cpf1 orthologs for activity in eukaryotic cells. Four of these new enzymes demonstrated targeted activity, one of which, from Moraxella bovoculi AAX11_00205 (Mb3Cpf1), exhibited robust indel formation. We also show that Mb3Cpf1 displays some tolerance for a shortened PAM (TTN versus the canonical Cpf1 PAM TTTV). The addition of these enzymes to the genome editing toolbox will further expand the utility of this powerful technology.
BibTeX
@misc{zetsche2017survey,
  author = {Bernd Zetsche and Jonathan Strecker and Omar O. Abudayyeh and Jonathan S. Gootenberg and David Scott and Feng Zhang},
  title = {{A Survey of Genome Editing Activity for 16 Cpf1 orthologs}},
  year = {2017},
  doi = {10.1101/134015},
  howpublished = {bioRxiv},
}
Figure